BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21314488)

  • 1. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center.
    El-Galaly T; Prakash V; Christiansen I; Madsen J; Johansen P; Boegsted M; Johnsen HE; Bukh A
    Leuk Lymphoma; 2011 Apr; 52(4):597-603. PubMed ID: 21314488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
    Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.
    Picardi M; Pugliese N; Cirillo M; Zeppa P; Cozzolino I; Ciancia G; Pettinato G; Salvatore C; Quintarelli C; Pane F
    Radiology; 2014 Jul; 272(1):262-74. PubMed ID: 24708193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.
    Dann EJ; Berkahn L; Mashiach T; Frumer M; Agur A; McDiarmid B; Bar-Shalom R; Paltiel O; Goldschmidt N
    Br J Haematol; 2014 Mar; 164(5):694-700. PubMed ID: 24313286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.
    El-Galaly TC; Mylam KJ; Brown P; Specht L; Christiansen I; Munksgaard L; Johnsen HE; Loft A; Bukh A; Iyer V; Nielsen AL; Hutchings M
    Haematologica; 2012 Jun; 97(6):931-6. PubMed ID: 22207683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
    García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
    Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
    Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography scanning in the assessment of patients with lymphoma.
    Foo SS; Mitchell PL; Berlangieri SU; Smith CL; Scott AM
    Intern Med J; 2004 Jul; 34(7):388-97. PubMed ID: 15271172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
    Goldschmidt N; Or O; Klein M; Savitsky B; Paltiel O
    Ann Hematol; 2011 Feb; 90(2):165-71. PubMed ID: 20706721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy.
    Cheah CY; Dickinson M; Hofman MS; George A; Ritchie DS; Prince HM; Westerman D; Harrison SJ; Burbury K; Wolf M; Januszewicz H; Herbert KE; Carney DA; Tam C; Seymour JF
    Ann Hematol; 2014 Jul; 93(7):1193-200. PubMed ID: 24595733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
    Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
    Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.
    Bhojwani D; McCarville MB; Choi JK; Sawyer J; Metzger ML; Inaba H; Davidoff AM; Gold R; Shulkin BL; Sandlund JT
    Br J Haematol; 2015 Mar; 168(6):845-53. PubMed ID: 25382494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of Histologic Verification of Positive Positron Emission Tomography/Computed Tomography Findings in the Follow-Up of Patients With Malignant Lymphoma.
    Nakayama H; Aisa Y; Ito C; Shimazaki K; Katsumata Y; Hayashi H; Nakazato T
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):753-60. PubMed ID: 26336914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
    Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.